Search alternatives:
point decrease » point increase (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
point decrease » point increase (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
-
781
-
782
-
783
S-glutathionylation catalyst diamide also decreases ROS release from permeabilized skeletal muscle mitochondria.
Published 2018“…The final concentration of pyruvate, 2-oxoglutarate, succinate, or palmitoyl-carnitine was 50 μM. n = 4, mean±SEM. (B) The decrease in mitochondrial ROS release correlates with an increase in overall protein S-glutathionylation. …”
-
784
-
785
-
786
Loss of ALS2 results in decreased levels of the lysosome-dependent degradation of LC3 in fibroblasts.
Published 2010“…Fibroblasts from wild-type (WT) and <i>Als2</i><sup>−/−</sup> mice were either left unstarved (0 hr) (upper) or starved for 6 hr (lower). It is notable that a 6 hr of starvation leads to decreased levels of the LC3- and p62-immunoreactive signals in WT cells, but not in <i>Als2</i><sup>−/−</sup> cells. …”
-
787
-
788
-
789
-
790
-
791
-
792
<i>sf3b1</i> mutant strains are defective in reproduction, development and fungi-infection resistance.
Published 2021“…Fecundity was measured over a period of 12 days from females crossed with the <i>WT</i> males, and each time point represents data from ten female adults. …”
-
793
-
794
-
795
-
796
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Published 2015“…Compound <b>26a</b> was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.…”
-
797
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Published 2015“…Compound <b>26a</b> was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.…”
-
798
-
799
-
800